z-logo
open-access-imgOpen Access
New Human Oral Squamous Carcinoma Cell Line and Its Tumorigenic Subline Producing Granulocyte Colony‐stimulating Factor
Author(s) -
Matsuo Kou,
Ishibashi Yukiko,
Kobayashi Ieyoshi,
Ozeki Satoru,
Ohishi Masamichi,
Tange Tsuyoshi,
Hirata Jouji,
Kiyoshima Tamotsu,
Sakai Hidetaka
Publication year - 1994
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1994.tb02938.x
Subject(s) - cell culture , matrigel , biology , epidermoid carcinoma , cancer research , cell , pathology , haematopoiesis , carcinoma , granulocyte , lymph node , stem cell , immunology , medicine , microbiology and biotechnology , biochemistry , genetics
A new human carcinoma cell line, MISK81‐5, was established from a metastatic lymph node of oral squamous cell carcinoma. Immunocytochemical and ultrastructural observations revealed an obvious epithelial origin of the cell line. Chromosome analysis revealed a hypertriploid karyotype with numerical and structural anomalies. MISK81‐5 cells could form a tumor mass in the subcutaneous tissue of recipient BALB/c athymic mice only when coinjected with Matrigel. A stem cell assay revealed that conditioned medium (CM) of MISK81‐5 contained granulocyte colony‐stimulating factor (G‐CSF) or interleukin‐6 activity. Quantitation by ELISA disclosed a higher concentration of G‐CSF in the CM of MISK81‐5 than in the CM of other squamous and gastric carcinoma cell lines. The sMISK, that was derived from MISK81‐5 as a subpopulation of the cell line having higher tumorigenicity, also showed a similar hematopoietic stimulating activity to that of MISK81‐5. These characteristics of the MISK81‐5 cell line and its subpopulation, sMISK will be useful for studying the biological behavior of oral squamous cell carcinomas and its relation to hematopoietic stimulating factors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here